Atossa Therapeutics (NASDAQ:ATOS) Posts Earnings Results

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) released its quarterly earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, Yahoo Finance reports.

Atossa Therapeutics Price Performance

Shares of ATOS opened at $1.84 on Wednesday. The stock has a 50-day moving average price of $1.17 and a 200 day moving average price of $0.90. Atossa Therapeutics has a one year low of $0.59 and a one year high of $2.11.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ATOS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Atossa Therapeutics in a research note on Friday, January 12th. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Atossa Therapeutics in a research note on Tuesday.

Get Our Latest Report on Atossa Therapeutics

Institutional Trading of Atossa Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP increased its position in shares of Atossa Therapeutics by 29.3% during the 4th quarter. GSA Capital Partners LLP now owns 449,082 shares of the company’s stock valued at $395,000 after purchasing an additional 101,690 shares during the period. Northern Trust Corp boosted its position in Atossa Therapeutics by 6.2% during the fourth quarter. Northern Trust Corp now owns 227,922 shares of the company’s stock valued at $201,000 after purchasing an additional 13,280 shares during the last quarter. UBS Group AG acquired a new stake in Atossa Therapeutics during the third quarter valued at $25,000. XTX Topco Ltd acquired a new stake in Atossa Therapeutics during the second quarter valued at $50,000. Finally, Two Sigma Securities LLC acquired a new stake in Atossa Therapeutics during the second quarter valued at $32,000. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Featured Stories

Earnings History for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.